« Return to News | Awards & Advancement

H3 Biomedicine names CEO

Thursday, November 3, 2011 10:27 AM

H3 Biomedicine has named Markus Warmuth, M.D., president and chief executive officer, effective immediately.

Warmuth joined the H3 Biomedicine team in August 2011 as chief scientific officer. Most recently, he had served as head of oncology drug discovery for the Novartis Institute for Biomedical Research (NIBR). In his role at NIBR, he directed broad aspects of the company's global oncology drug discovery portfolio from target discovery to clinical development.

"Markus provides the scientific vision of human cancer genetics revealing cancer dependencies and targeting those dependencies, even when they are viewed as challenging, by exploiting advances in modern asymmetric synthesis and chemical biology. He also brings industrial experience in leadership, management and cancer drug development. He is a perfect fit for the intensive, fast-paced environment of H3, where we want to bring hope and health urgently to patients living with cancer," said Stuart L. Schreiber, Ph.D., H3 scientific founder and founding director of Chemical Biology at the Broad Institute of Harvard and MIT.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.